Jared Kelly
Fortuna: 118 612 $ al 31/05/2026
Fortuna: 118 612 $ al 31/05/2026
Jared Kelly is currently Chief Executive Officer & Director at Oncolytics Biotech, Inc. since 2025.
Mr. Kelly is also Secretary, Senior Vice President & General Counsel at Ambrx Biopharma Cayman, Inc. since 2023.
Formerly, Mr. Kelly was a Partner at Lowenstein Sandler LLP.
Mr. Kelly completed graduate studies at Georgetown University Law Center.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 01/06/2026 | 114.050 ( 0,1 % ) | 118 612 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Director Ejecutivo | 11/06/2025 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Consejero General | 13/09/2023 |
| Empresas | Cargo | Fin |
|---|---|---|
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
Lowenstein Sandler LLP
Lowenstein Sandler LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Georgetown University Law Center
Georgetown University Law Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biologics company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.